Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Hoth Therapeutics Inc

Current price
1.16 USD +0.04 USD (+3.57%)
Last closed 1.12 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 4 824 548 USD
Yield for 12 month -69.15 %
21.11.2021 - 28.11.2021

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. Address: 1 Rockefeller Plaza, New York, NY, United States, 10020


WallStreet Target Price

4.75 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-66 834 USD

Last Year

-46 871 000 USD

Current Quarter

-6 752 USD

Last Quarter

-7 897 USD

Key Figures HOTH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -14 100 397 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -53.54 %
PEG Ratio
Return On Equity TTM -100.65 %
Wall Street Target Price 4.75 USD
Revenue TTM
Book Value 2.42 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -4.71 USD
Diluted Eps TTM -4.71 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics HOTH

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History HOTH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:25
Payout Ratio
Last Split Date 26.10.2022
Dividend Date

Stock Valuation HOTH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA 0.4654
Price Book MRQ 0.4802

Financials HOTH

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators HOTH

For 52 weeks

0.99 USD 12.5 USD
50 Day MA 1.34 USD
Shares Short Prior Month 81 467
200 Day MA 2.12 USD
Short Ratio 0.42
Shares Short 24 820
Short Percent 0.65 %